Melanotan I
- Category
- Skin & Cosmetic
- Administration routes
- Injectable
- Regulatory status
- FDA-approved
What it is
A linear alpha-MSH analog that binds MC1R to raise eumelanin, sold as an approved implant and also used, outside its approval, for cosmetic tanning. Evidence for EPP photoprotection is solid; quality-of-life and vitiligo gains are moderate; other claims are speculative. Skin darkening is expected, and nausea affected 19% in the FDA trial safety population. Moles need monitoring, and unregulated products carry melanoma case reports. Approved only for EPP; cosmetic tanning relies on unregulated products sold online.
Read Full recordStudied uses & evidence
Studied uses(8)
Photoprotection in EPP
HighTwo blinded, placebo-controlled trials enrolled 168 patients: 74 in the EU and 94 in the US.
Eumelanin production without UV
HighSkin darkening was recorded as a trial-confirmed effect in vehicle-controlled human studies, without UV exposure.
Quality of life improvement in EPP
MediumQuality-of-life gains were a secondary endpoint in RCTs, with further support from a retrospective cohort study.
Evidence limits
- Evidence Level
- Level 1 — FDA Approved
Two pivotal Phase III multicenter, randomized, double-blind, placebo-controlled trials (168 patients total: 74 EU, 94 US). Additional Phase II/III trials in vitiligo, polymorphic light eruption, and other photodermatoses. FDA approval based on 3 trials totaling 244 adults across 22 US and European sites. Post-marketing observational data from 200-patient German cohort confirms long-term safety.
Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Cautions & risk summary
General cautions
Pregnancy or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Children under 18
AbsoluteNo pediatric safety data. Not recommended for use in minors.
Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
Risk summary(9)
Risks = level of concern: High · Moderate · Low · Theoretical
Nausea and headache (very common, >10% of patients)
ModerateImplant site reactions including bruising and discomfort
HighDarkening of existing moles — requires regular dermatologic monitoring for melanocytic changes
HighDiffuse skin hyperpigmentation experienced by nearly all patients
HighRare serious hypersensitivity reactions including anaphylaxis (post-marketing reports)
ModerateNew melanocytic nevi may develop during treatment
LowUnregulated melanotan products: 4 case reports of melanoma emergence, unknown purity/dosing, melanocytic changes in moles and dysplastic nevi
ModerateSafety not established in children, pregnancy/breastfeeding, or patients with liver/kidney impairment
ModerateLong-term effects of repeated eumelanin stimulation beyond clinical trial durations not fully characterized
Theoretical
Further reading
- Overview in Full record
- Safety & interactions in Full record
- Research & benefits in Full record
- Prescribing labels in Full record
- Monitoring & labs in Full record
- Regulation & availability in Full record
- Sources in Full record
- Frequently asked questions in Full record
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.